Strategic collaborations Sygnature Discovery is a global drug discovery CRO with a track record of delivering integrated services across target identification to candidate nomination, presenting opportunities to propose expanded engagements with pharma and biotech clients seeking end-to-end discovery partnerships.

Strong client retention With over 90 percent of customers staying with Sygnature, there is a proven relationship moat and potential for multi-project expansions, cross-selling of additional platforms, and longer-term strategic collaborations.

Therapeutic focus Core emphasis on oncology, inflammation and immunology, neuroscience, metabolic diseases, respiratory, infectious diseases and fibrotic diseases aligns with high-value, high-demand areas where pharma and biotech clients are actively investing and seeking specialized expertise.

Technology enablement Recent introductions such as ExpiCHO-S, recombinant Factor C endotoxin assay, and advanced computational tools (SygDesign, BullFrog AI, Iktos) indicate a technology-forward approach that can be leveraged to pitch faster, higher-quality discovery workflows and reduced timelines.

Scale and capability A large, multinational team of 700+ scientists across Europe and North America with diverse expertise in protein science, chemistry, computational chemistry, in vitro biology, pharmacology, and DMPK enables high-complexity projects and offers opportunities to upsell integrated services and geographic coverage.